[go: up one dir, main page]

MX2009009738A - Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento. - Google Patents

Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.

Info

Publication number
MX2009009738A
MX2009009738A MX2009009738A MX2009009738A MX2009009738A MX 2009009738 A MX2009009738 A MX 2009009738A MX 2009009738 A MX2009009738 A MX 2009009738A MX 2009009738 A MX2009009738 A MX 2009009738A MX 2009009738 A MX2009009738 A MX 2009009738A
Authority
MX
Mexico
Prior art keywords
complement factor
inhibitors
age
treatment
macular degeneration
Prior art date
Application number
MX2009009738A
Other languages
English (en)
Inventor
Carmelo Romano
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2009009738A publication Critical patent/MX2009009738A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención provee métodos para identificar a un paciente en riesgo para desarrollar AMD identificando la presencia del polimorfismo Y402H u otro en variantes en riesgo en el gen de facto RH de complemento. La presente invención provee además métodos para tratar a personas que tienen AMD o que están en riesgo de desarrollar AMD como resultado de tener polimorfismo de Y402H u toras variantes en riesgo en el gen de factor H de complemento.
MX2009009738A 2007-04-30 2008-04-07 Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento. MX2009009738A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91487707P 2007-04-30 2007-04-30
PCT/US2008/059556 WO2008137236A2 (en) 2007-04-30 2008-04-07 Treatment of age-related macular degeneration using inhibitors of complement factor d

Publications (1)

Publication Number Publication Date
MX2009009738A true MX2009009738A (es) 2009-09-24

Family

ID=39586997

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009738A MX2009009738A (es) 2007-04-30 2008-04-07 Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.

Country Status (15)

Country Link
US (1) US20080269318A1 (es)
EP (1) EP2139471A2 (es)
JP (1) JP2010526074A (es)
KR (1) KR20100014486A (es)
CN (1) CN101674824A (es)
AR (1) AR066292A1 (es)
AU (1) AU2008248043A1 (es)
BR (1) BRPI0811007A2 (es)
CA (1) CA2680833A1 (es)
CL (1) CL2008001259A1 (es)
MX (1) MX2009009738A (es)
RU (1) RU2009144142A (es)
TW (1) TW200900056A (es)
UY (1) UY31061A1 (es)
WO (1) WO2008137236A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2450771C (en) 2001-06-12 2010-09-07 Johns Hopkins University School Of Medicine Reservoir device for intraocular drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
SG2014007389A (en) 2009-01-29 2014-04-28 Forsight Vision4 Inc Posterior segment drug delivery
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
CN105435338B (zh) 2010-08-05 2019-03-26 弗赛特影像4股份有限公司 用于药物输送的注入器装置和方法
HRP20211909T1 (hr) 2010-08-05 2022-03-18 Forsight Vision4, Inc. Uređaj za liječenja oka
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
RU2495650C1 (ru) * 2012-02-29 2013-10-20 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Трехкомпонентный комплекс для клеточной терапии в офтальмологии
RU2485922C1 (ru) * 2012-03-28 2013-06-27 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ лечения "сухой" формы возрастной макулярной дегенерации
RU2494711C1 (ru) * 2012-05-18 2013-10-10 Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации Способ хирургического лечения прогрессирующей и осложненной миопии
CA2905496A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
BR112016002845A2 (pt) * 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
EP3041524A4 (en) 2013-09-06 2017-06-14 The Regents of the University of Colorado, a body corporate Intraocular drug delivery and filter device and methods of using same
US11219552B2 (en) 2013-09-06 2022-01-11 The Regents Of The University Of Colorado, A Body Corporate Intraocular filter device and methods of using same
US20160237146A1 (en) * 2013-10-07 2016-08-18 Massachusetts Eye And Ear Infirmary Methods of Preventing or Reducing Photoreceptor Cell Death
DE102014107380A1 (de) 2014-05-26 2015-11-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür
EP3973994A1 (en) 2014-06-12 2022-03-30 RA Pharmaceuticals, Inc. Modulation of complement activity
SG11201700943TA (en) 2014-08-08 2017-03-30 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
ES2900998T3 (es) 2015-01-28 2022-03-21 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
WO2017087902A1 (en) 2015-11-20 2017-05-26 Forsight Vision4, Inc. Porous structures for extended release drug delivery devices
RS64067B1 (sr) 2015-12-16 2023-04-28 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
AU2017210042B2 (en) * 2016-01-20 2021-01-21 396419 B.C. Ltd. Compositions and methods for inhibiting Factor D
CN110087668A (zh) 2016-12-07 2019-08-02 Ra制药公司 补体活性的调节剂
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
WO2018191548A2 (en) 2017-04-14 2018-10-18 Kodiak Sciences Inc. Complement factor d antagonist antibodies and conjugates thereof
MX2020005547A (es) 2017-12-04 2020-08-20 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
WO2020185541A2 (en) 2019-03-08 2020-09-17 Ra Pharmaceuticals, Inc. Modulators of complement activity
WO2020205501A1 (en) 2019-03-29 2020-10-08 Ra Pharmaceuticals, Inc. Complement modulators and related methods
CN113710230A (zh) 2019-04-24 2021-11-26 Ra制药公司 用于调节补体活性的组合物和方法
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. METHOD FOR TREATING AN EYE DISORDER
BR112022022980A2 (pt) 2020-05-12 2022-12-20 Alexion Pharma Inc Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna
CN114686481B (zh) * 2020-12-31 2023-08-15 北京键凯科技股份有限公司 一种抑制cfd表达的干扰rna及其制备方法和应用
WO2025199107A1 (en) 2024-03-19 2025-09-25 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6653340B1 (en) * 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
ATE290837T1 (de) * 1999-10-21 2005-04-15 Alcon Inc Medikamentenversorgung der sub-tenon
CA2407715C (en) * 2000-04-29 2009-03-24 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
NZ608860A (en) * 2005-02-14 2014-10-31 Univ Iowa Res Found Methods and reagents for treatment and diagnosis of age-related macular degeneration
US8580735B2 (en) * 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders

Also Published As

Publication number Publication date
RU2009144142A (ru) 2011-06-10
AU2008248043A1 (en) 2008-11-13
TW200900056A (en) 2009-01-01
JP2010526074A (ja) 2010-07-29
WO2008137236A2 (en) 2008-11-13
CN101674824A (zh) 2010-03-17
AR066292A1 (es) 2009-08-12
UY31061A1 (es) 2008-10-31
CL2008001259A1 (es) 2009-01-02
BRPI0811007A2 (pt) 2015-01-27
US20080269318A1 (en) 2008-10-30
WO2008137236A3 (en) 2009-02-05
EP2139471A2 (en) 2010-01-06
KR20100014486A (ko) 2010-02-10
CA2680833A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
MX2009009738A (es) Tratamiento de degeneracion macular relacionada con la edad usando inhibidores de factor d de complemento.
MX2007009565A (es) Metodos y reactivos para tratamiento y diagnostico de degeneracion macular relacionada con la edad.
TW200716141A (en) Compositions and methods for treatment for neoplasms
MX2007007919A (es) Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
UA118645C2 (uk) Спосіб комбінованої терапії раку наночастинками, що містять рапаміцин і альбумін
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ZA201005922B (en) Method of treatment of age-related macular degeneration (amd)
ATE530142T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
TW200806325A (en) Therapeutic uses of inhibitors of RTP801
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
WO2007141796A3 (en) Therapeutic uses of inhibitors of rtp801l
WO2009025806A3 (en) Use of vegfr-2 inhibitors for treating metastatic cancer
TW200731984A (en) C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor H
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
AR067395A1 (es) Inhibicion de htra1 mediada por iarn para el tratamiento de la degeneracion macular
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
MX2009004402A (es) Uso de gen de amiloide serico en el diagnostico y tratamiento de glaucoma e identificacion de agentes anti-glaucoma.
WO2009129497A3 (en) Methods and compositions for treating age-related macular degeneration
EP2046366A4 (en) METHOD OF TREATING AGE-RELATED MACULAR DEGENERATION
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
WO2009109862A3 (en) S100a6 and/or s100a4 inhibitors for treating cancer
WO2008022155A3 (en) Methods of identifying agents for treating neurological disorders
TW200744585A (en) Inhibitors of PAI-1 for treatment of muscular conditions